Dr Robert Nordon graduated from the University of New South Wales in 1986 with an MBBS and received his PhD in the field of Biomedical Engineering in 1994. He undertook postdoctoral research in The Terry Fox Laboratory in Vancouver, Canada, in experimental haematology, before returning to UNSW in 1997 to continue postdoctoral studies in the Graduate School of Biomedical Engineering on an ARC Australian Post-Doctoral Fellowship, and he has been Senior Lecturer in the same department since 2006.

Dr Nordon is considered a National authority in the area of mammalian cell bioreactors for clinical therapies. He is the inventor of a hollow fibre bioreactor that was commercialised by a US blood component therapy company, Ceridian BCT (formally Gambro, BCT). Dr Nordon has also made significant contributions in the field of analytical cytology, which is highly relevant to this proposal. He has developed experimental and theoretical methods for analysis of multipotent cell differentiation, which is now widely cited in the literature. 

He is currently refining methods for single cell fate mapping using “lab-on-a-chip” devices. His role in the Stem Cells Australia will be to collaborate with the Harvey laboratory in single cell real time analysis of cardiac stem cell growth and differentiation using microfluidics technology.